• Rani Therapeutics CEO Imran Talat bought 35,000 Class A common shares in an open-market purchase.
• Purchase price was USD 0.72 per share.
• Talat’s direct holding rose to 469,736 Class A common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001869579-26-000007), on July 21, 2026, and is solely responsible for the information contained therein.